Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aditxt, Inc. stock logo
ADTX
Aditxt
$1.23
-1.9%
$1.64
$1.11
$27,200.00
$2.60M1.49909,938 shs349,305 shs
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
$0.00
$0.00
$0.00
$710K-0.2156,884 shsN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$5.38
-4.8%
$4.69
$2.92
$699.19
$3.07M0.22113,340 shs28,644 shs
PainReform Ltd. stock logo
PRFX
PainReform
$1.43
+2.4%
$1.89
$1.25
$16.63
$2.88M0.561.45 million shs14,291 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aditxt, Inc. stock logo
ADTX
Aditxt
-1.92%-21.41%-19.87%-74.08%-99.99%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00%0.00%0.00%-50.00%0.00%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
-4.76%+6.74%+10.27%+46.14%-97.02%
PainReform Ltd. stock logo
PRFX
PainReform
+2.43%-1.10%-29.01%-31.39%-21.88%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aditxt, Inc. stock logo
ADTX
Aditxt
N/AN/AN/AN/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
0.7608 of 5 stars
0.04.00.00.00.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aditxt, Inc. stock logo
ADTX
Aditxt
0.00
N/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
0.00
N/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
0.00
N/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aditxt, Inc. stock logo
ADTX
Aditxt
$130K19.99N/AN/A($1.52) per share-0.81
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/A$1.70 per share3.16$11.80 per shareN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/A$2.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aditxt, Inc. stock logo
ADTX
Aditxt
-$34.45MN/A0.00N/A-46,082.47%-389.10%-84.71%8/18/2025 (Estimated)
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
$1.01MN/A0.00N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
-$14.59M-$147.33N/AN/AN/AN/AN/A8/21/2025 (Estimated)

Latest NPHC, PRFX, ADTX, and PBM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Aditxt, Inc. stock logo
ADTX
Aditxt
-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aditxt, Inc. stock logo
ADTX
Aditxt
N/AN/AN/AN/AN/A
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/AN/AN/AN/AN/A
PainReform Ltd. stock logo
PRFX
PainReform
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aditxt, Inc. stock logo
ADTX
Aditxt
N/A
0.08
0.08
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/AN/AN/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A
11.04
11.04
PainReform Ltd. stock logo
PRFX
PainReform
N/A
1.81
1.81

Institutional Ownership

CompanyInstitutional Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
15.54%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
N/A
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
77.44%
PainReform Ltd. stock logo
PRFX
PainReform
37.28%

Insider Ownership

CompanyInsider Ownership
Aditxt, Inc. stock logo
ADTX
Aditxt
0.01%
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
61.50%
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
3.60%
PainReform Ltd. stock logo
PRFX
PainReform
34.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aditxt, Inc. stock logo
ADTX
Aditxt
602.12 million2.12 millionNo Data
Nutra Pharma Corp. stock logo
NPHC
Nutra Pharma
47.10 billion2.73 billionNot Optionable
Psyence Biomedical Ltd. stock logo
PBM
Psyence Biomedical
N/A570,000549,000N/A
PainReform Ltd. stock logo
PRFX
PainReform
42.01 million1.32 millionNot Optionable

Recent News About These Companies

PainReform Ltd.
PainReform announces expansion into SEM sector
PainReform Ltd: PainReform Provides Year-End Business Update
PainReform says shareholder equity now exceeds required threshold
PainReform Provides Year-End Business Update
PainReform acquires AI solar analytics firm DeepSolar
PainReform completes acquisition of DeepSolar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aditxt stock logo

Aditxt NASDAQ:ADTX

$1.23 -0.02 (-1.92%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$1.22 -0.01 (-0.90%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Nutra Pharma stock logo

Nutra Pharma OTCMKTS:NPHC

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.

Psyence Biomedical stock logo

Psyence Biomedical NASDAQ:PBM

$5.38 -0.27 (-4.76%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$5.41 +0.03 (+0.61%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.

PainReform stock logo

PainReform NASDAQ:PRFX

$1.43 +0.03 (+2.43%)
As of 07/3/2025 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.